1. Home
  2. DLNG vs LCTX Comparison

DLNG vs LCTX Comparison

Compare DLNG & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLNG
  • LCTX
  • Stock Information
  • Founded
  • DLNG 2013
  • LCTX 1990
  • Country
  • DLNG Greece
  • LCTX United States
  • Employees
  • DLNG N/A
  • LCTX N/A
  • Industry
  • DLNG Marine Transportation
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DLNG Consumer Discretionary
  • LCTX Health Care
  • Exchange
  • DLNG Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • DLNG 133.4M
  • LCTX 107.3M
  • IPO Year
  • DLNG 2013
  • LCTX N/A
  • Fundamental
  • Price
  • DLNG $3.57
  • LCTX $0.90
  • Analyst Decision
  • DLNG
  • LCTX Strong Buy
  • Analyst Count
  • DLNG 0
  • LCTX 5
  • Target Price
  • DLNG N/A
  • LCTX $4.20
  • AVG Volume (30 Days)
  • DLNG 40.2K
  • LCTX 2.3M
  • Earning Date
  • DLNG 05-27-2025
  • LCTX 08-07-2025
  • Dividend Yield
  • DLNG 5.57%
  • LCTX N/A
  • EPS Growth
  • DLNG 53.29
  • LCTX N/A
  • EPS
  • DLNG 1.10
  • LCTX N/A
  • Revenue
  • DLNG $157,455,000.00
  • LCTX $9,557,000.00
  • Revenue This Year
  • DLNG N/A
  • LCTX N/A
  • Revenue Next Year
  • DLNG $0.37
  • LCTX $232.66
  • P/E Ratio
  • DLNG $3.30
  • LCTX N/A
  • Revenue Growth
  • DLNG N/A
  • LCTX 19.42
  • 52 Week Low
  • DLNG $3.18
  • LCTX $0.37
  • 52 Week High
  • DLNG $5.65
  • LCTX $1.15
  • Technical
  • Relative Strength Index (RSI)
  • DLNG 44.10
  • LCTX 74.23
  • Support Level
  • DLNG $3.50
  • LCTX $0.67
  • Resistance Level
  • DLNG $3.71
  • LCTX $0.83
  • Average True Range (ATR)
  • DLNG 0.10
  • LCTX 0.06
  • MACD
  • DLNG -0.01
  • LCTX 0.02
  • Stochastic Oscillator
  • DLNG 25.00
  • LCTX 84.94

About DLNG Dynagas LNG Partners LP Common Units

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: